Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, et al. Dupilumab provides favourable long-term safety and efficacy in children aged >/= 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol 2020 Sep 24. doi: 10.1111/bjd.19460.
PMID: 32969489


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016